NCT04010357 2025-12-02
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
Case Comprehensive Cancer Center
Phase 2 Active not recruiting
Clinical Trials
4 trialsNCT04545710 2024-08-05
Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance
University of California, San Diego
Phase 2 Active not recruiting
NCT03654833 2023-03-14
MiST
University of Leicester
Phase 2 Unknown
NCT02450539 2021-08-13
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed